Role of miR-15/16 in CLL

[1]  M. Williams,et al.  Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Ana Kozomara,et al.  miRBase: annotating high confidence microRNAs using deep sequencing data , 2013, Nucleic Acids Res..

[3]  B. Liu,et al.  MicroRNA-16 inhibits bladder cancer proliferation by targeting Cyclin D1. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[4]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[5]  Kang Han,et al.  miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. , 2012, Oncology reports.

[6]  V. Puduvalli,et al.  Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. , 2012, Blood.

[7]  A. Strasser,et al.  Pharmacological blockade of Bcl-2, Bcl-xL and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice , 2011, Cell Death and Differentiation.

[8]  George A Calin,et al.  Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. , 2011, JAMA.

[9]  Y. Pekarsky,et al.  13q14 deletions in CLL involve cooperating tumor suppressors. , 2010, Blood.

[10]  Andrea Califano,et al.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. , 2010, Cancer cell.

[11]  C. Croce,et al.  MiR-15a and miR-16-1 cluster functions in human leukemia , 2008, Proceedings of the National Academy of Sciences.

[12]  M. Kaminski,et al.  Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. , 2008, Cancer research.

[13]  Pablo Landgraf,et al.  Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. , 2007, Blood.

[14]  Y. Pekarsky,et al.  Animal models for chronic lymphocytic leukemia , 2007, Journal of cellular biochemistry.

[15]  F. Ajchenbaum‐Cymbalista,et al.  Role of BAFF and APRIL in human B‐cell chronic lymphocytic leukaemia , 2006, Immunology.

[16]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[17]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  John Calvin Reed,et al.  TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[20]  D. Catovsky.  Definition and diagnosis of sporadic and familial chronic lymphocytic leukemia. , 2004, Hematology/oncology clinics of North America.

[21]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[22]  D. Grandér,et al.  Characterization of a novel B‐CLL candidate gene – DLEU7 – located in the 13q14 tumor suppressor locus , 2004, FEBS letters.

[23]  P. Schneider,et al.  BAFF AND APRIL: a tutorial on B cell survival. , 2003, Annual review of immunology.

[24]  V. Ambros,et al.  MicroRNA Pathways in Flies and Worms Growth, Death, Fat, Stress, and Timing , 2003, Cell.

[25]  A. Sánchez-Aguilera,et al.  Cell cycle deregulation in B-cell lymphomas. , 2003, Blood.

[26]  D. Catovsky,et al.  Delineation of the minimal region of loss at 13q14 in multiple myeloma , 2003, Genes, chromosomes & cancer.

[27]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Döhner,et al.  Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. , 2002, Blood.

[29]  M. Batzer,et al.  Comprehensive analysis of a large genomic sequence at the putative B-cell chronic lymphocytic leukaemia (B-CLL) tumour suppresser gene locus. , 2001, Mutation research.

[30]  H. Frierson,et al.  Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer , 2001, The Prostate.

[31]  Y. Pekarsky,et al.  Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. , 2001, Cancer research.

[32]  Minchen Chien,et al.  Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. , 2001, Blood.

[33]  R. Berland,et al.  An NFAT-dependent enhancer is necessary for anti-IgM-mediated induction of murine CD5 expression in primary splenic B cells. , 1998, Journal of immunology.

[34]  C. Croce,et al.  Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. , 1998, Blood.

[35]  Stephan Wolf,et al.  Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma , 1998, Oncogene.

[36]  John Calvin Reed.  Molecular biology of chronic lymphocytic leukemia. , 1998, Seminars in oncology.

[37]  M. Nussenzweig,et al.  TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival. , 1997, Immunity.

[38]  E. Serfling,et al.  Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients. , 1996, Leukemia & lymphoma.

[39]  J C Reed,et al.  Differential effects of Bcl-2 on T and B cells in transgenic mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[40]  E. Raveche,et al.  Possible immunoregulatory role for CD5 + B cells. , 1990, Clinical immunology and immunopathology.

[41]  T. Kipps,et al.  Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia , 1990, The Journal of experimental medicine.

[42]  Y. Tsujimoto,et al.  Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.

[43]  P. Nowell,et al.  Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. , 1984, Science.

[44]  Medical Faculty,et al.  High-Resolution Genomic Profiling of Chronic Lymphocytic Leukemia Reveals New Recurrent Genomic Alterations , 2014 .

[45]  H. Döhner,et al.  Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia , 2014, Leukemia.

[46]  手島 和暁,et al.  Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma , 2013 .

[47]  ONSTANZE,et al.  GENOMIC ABERRATIONS AND SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA , 2010 .

[48]  Y. Pekarsky,et al.  Chronic lymphocytic leukemia: molecular genetics and animal models. , 2005, Current topics in microbiology and immunology.

[49]  W. Wierda.  Molecular Biology of Chronic Lymphocytic Leukemia , 2004 .